Researchers use CAR T-cell therapy to pursue new prostate cancer target
Click Here to Manage Email Alerts
An immunotherapy regimen featuring a novel chimeric antigen receptor T-cell therapy demonstrated antitumor activity against metastatic prostate cancer models, study results published in Nature Communications showed.
An international group of researchers evaluated the safety and efficacy of a CAR T-cell therapy construct that targets the antigen six transmembrane epithelial antigen of the prostate 1 (STEAP1) on the surface of cancer cells.
Investigators administered the investigational cellular therapy in combination with a collagen binding domain–interleukin-12 fusion protein given locally at the tumor site in metastatic prostate cancer models.
Researchers observed antitumor activity capable of delaying disease progression or eradicating tumors at target sites despite a low density of target antigen on tumor cell surfaces.
Healio spoke with John K. Lee, MD, PhD, assistant professor in the human biology and clinical research divisions at Fred Hutchinson Cancer Center, about the results and his group’s plans to evaluate the STEAP1-directed CAR-T in a phase 1 clinical trial.
Collapse
Read more about
Click Here to Manage Email Alerts